Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

Sartorius and HOF Sonderanlagenbau Partnership Creates Streamlined Offering of Freeze-Thaw Solutions for Biological Products

publication date: Feb 4, 2022
 | 
author/source: Sartorius Group

sartorius-and-hof-sonderanlagenbau-partnership-creates

Integration of HOF horizontal plate freezers into Sartorius Celsius® portfolio simplifies management of drug substance storage and shipping for biopharmaceutical manufacturers.

Sartorius (DAX: SRT:GR) and HOF Sonderanlagenbau, have announced a partnership to integrate two HOF horizontal plate freeze-thaw units into Sartorius’ portfolio offering customers a full suite of compatible freeze-thaw equipment and consumables.  This partnership will enable faster and easier implementation of robust frozen drug substance management platforms through improved validation and purchase support from a single supplier.

“With this partnership, Sartorius continues to strengthen its leading position in the freeze-thaw market,” said Eva Lindskog, Head of Fluid Management Technologies at Sartorius. “The combination of our robust Celsius® single-use containers with market-leading freeze-thaw equipment from HOF will provide our customers with a simplified supply chain for improved management of drug substance.”

A key criterion in the drug substance freeze-thaw process is the ability to reliably control cooling and heating to prevent cryo-concentration. The combination of the new Celsius® consumables, with HOF’s adjustable plate system, provides predictability, robustness, and reproducibility.

Alexander Hof, CEO at HOF Sonderanlagenbau GmbH said, “Our customers that need to freeze during their processes are seeking the best available solutions. The unique combination of our reliable HOF freeze-thaw units and Sartorius’ proven single-use technology consumables portfolio will enable drug manufacturers to progress toward high quality, secure drug substance freezing and thawing for a safer future.”

The partnership builds on Sartorius’ 15-year success in developing proven freeze-thaw solutions for customers worldwide and reinforces the company’s commitment to global access to cold chain product and process innovation.

 

View Celsius® portfolio

 

 

About HOF Sonderanlagenbau GmbH

HOF Sonderanlagenbau GmbH is the leading specialist for manufacturing high-quality, future-proof freeze drying systems, loading and unloading systems and freezing and thawing equipment for the pharmaceutical and biotech industries. Since its foundation in 1988 in the center of Germany, the company has consistently expanded its market share – today, HOF has over 300 employees who provide reliable and flexible services to national and international customers. The Sector for Freeze-Thaw Units found its base already in the early 1990s, primarily in the blood plasma sector and was further developed for pharmaceutical applications in the mid-2000s, resulting in over 350 units in the market. As quality and reliability are the crucial parameters for the success of a product, HOF is also the partner for all after-sales activities, servicing more than 2000 machines worldwide.

 

About Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

 

Recent news from Sartorius

 


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.